Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P L Iversen

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Current Opinion in Molecular Therapeutics|August 11, 2001
Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivationP L Iversen
Current Opinion in Molecular Therapeutics|August 11, 2001
Redirection of drug metabolism using antisense technologyV Arora, P L Iversen
General Pharmacology|November 1, 1994
Metallothionein in carcinogenesis and cancer chemotherapyM Ebadi, P L Iversen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 21, 2000
Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivoV Arora, P L Iversen
Antisense & Nucleic Acid Drug Development|September 13, 2000
Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomersC Ghosh, P L Iversen
The Journal of General Virology|October 1, 1989
Inhibition of human immunodeficiency virus type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligodeoxyribonucleotidesM Stevenson, P L Iversen
Biological Signals|March 1, 1992
Antisense oligonucleotide-mediated inhibition of metallothionein protein synthesis in neuroblastoma IMR 32 and Chang liver cells in cultureP L Iversen, M Ebadi
Advanced Drug Delivery Reviews|October 18, 2000
Transdermal delivery of antisense compoundsR M Brand, P L Iversen
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivoJ P Desjardins, P L Iversen
Pharmaceutical Research|June 1, 1996
Iontophoretic delivery of a telomeric oligonucleotideR M Brand, P L Iversen
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Current Opinion in Molecular Therapeutics|August 11, 2001
Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivationP L Iversen
Current Opinion in Molecular Therapeutics|August 11, 2001
Redirection of drug metabolism using antisense technologyV Arora, P L Iversen
General Pharmacology|November 1, 1994
Metallothionein in carcinogenesis and cancer chemotherapyM Ebadi, P L Iversen
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 21, 2000
Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivoV Arora, P L Iversen
Antisense & Nucleic Acid Drug Development|September 13, 2000
Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomersC Ghosh, P L Iversen
The Journal of General Virology|October 1, 1989
Inhibition of human immunodeficiency virus type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligodeoxyribonucleotidesM Stevenson, P L Iversen
Biological Signals|March 1, 1992
Antisense oligonucleotide-mediated inhibition of metallothionein protein synthesis in neuroblastoma IMR 32 and Chang liver cells in cultureP L Iversen, M Ebadi
Advanced Drug Delivery Reviews|October 18, 2000
Transdermal delivery of antisense compoundsR M Brand, P L Iversen
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivoJ P Desjardins, P L Iversen
Pharmaceutical Research|June 1, 1996
Iontophoretic delivery of a telomeric oligonucleotideR M Brand, P L Iversen
Pageof 8